Aclaris Therapeutics, Inc.
ACRS · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Feb 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $7.83M | $18.7M | −58.2% |
| Operating income | −$76.4M | −$142M | +46.2% |
| Net income | −$64.9M | −$132M | +50.8% |
Latest quarter: Q3 2026
Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 5, 2026
| $ | Q3 2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $1.50M | $3.30M | −54.5% |
| Operating income | −$21.3M | −$17.1M | −24.6% |
| Net income | −$18.5M | −$14.6M | −26.7% |
Q3 2026 dashboardQ3 2026 infographic
Questions
- What was Aclaris's revenue in FY2025?
- $7.83M in FY2025 (Fiscal year ended Dec 31, 2025), −58.2% vs $18.7M a year earlier, per its 10-K filed Feb 2026.
- Was Aclaris profitable in FY2025?
- No: net income was −$64.9M and operating income −$76.4M in FY2025.
- What was Aclaris's revenue in Q3 2026?
- $1.50M (−54.5% vs a year earlier), per its Form 10-Q filed Nov 5, 2026.